Sensyne Health PLC (AIM:SENS, FRA:DSH) said it signed a research agreement with Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH).
The five-year non-exclusive partnership is to analyse anonymised patient data using clinical artificial intelligence technology.
READ: Sensyne Health signs strategic research agreement with US healthcare group
They will focus on improving paediatric clinical outcomes and speeding up research into new medicines to find new and better ways to treat rare and complex childhood diseases.
It’s the first time Sensyne is working on a project specifically aimed at children.
The clinical AI group said this part of medicine has been “especially challenging” in terms of new therapies and in limiting the availability of paediatric versions of adult medicines.
The first project will focus on developing a clinical decision support algorithm to help clinicians caring for children with chronic kidney disease. This will then be used to develop further clinical support algorithms for other diseases in children.
Sensyne and GOSH will focus on three areas: paediatric drug discovery, clinical decision tools to support children's care and clinical trial design, all using AI technology.
They also plan to build a global ethical AI research paediatric community.
"We are delighted to be undertaking research in partnership with Great Ormond Street Hospital, widely recognised as one of the leading centres for children's healthcare and research in the world,” said Sensyne’s chief executive Lord Drayson.
“GOSH has invested heavily in its digital infrastructure and curation of its data which means we can start work immediately: together we aim to use the power of ethical AI to make a real difference in finding new and better ways to treat rare and complex childhood diseases and in future to develop a world-wide research community using ethical AI to improve the lives of children world-wide."